Gene gun application in the generation of effector T cells for adoptive immunotherapy

Cancer Immunology Immunotherapy

Volumn 48, Issue 11, 2000, Pages 635-643

  Tanigawa, Keishi ^a   Yu, Hua ^b   Sun, Rong ^a   Nickoloff, Brian J ^c   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Gene therapy; T cells; Vaccines

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GOLD; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENE GUN; GENE THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; TUMOR REGRESSION;

EID: 0033971582     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050012     Document Type: Article

References (33)

1. 1. Arca MJ, Krauss JC, Strome S, Cameron MJ, Chang AE (1996) Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 42:237
2. 2. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE (1996) Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 3:39
3. + T cells during tumor growth with antitumor reactivity in adoptive immunotherapy. J Immunol 20:138-145
4. 4. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE (1997) Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 159:664
5. 5. Aruga A, Aruga E, Chang AE (1997) Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res 57:3230
6. 6. Aruga A, Tanigawa K, Aruga E, Yu H, Chang AE (1999) Enhanced adjuvant effect of granulocyte-macrophage colonystimulating factor plus interleukin-12 compared with either alone or in vaccine-induced tumor immunity. Cancer Gene Ther 6:89
7. + effector cells in a murine mammary model. J Immunother (in press)
8. 8. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Shu S, Sondak VK (1993) Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043
9. 9. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S (1997) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796
10. 10. Chou T, Bertera S, Chang AE, Shu S (1988) Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141:1775
11. 11. Dranoff G, Jaffe E, Lazenby A, Golumbek P, Levitskyk HI, Brose K, Jackson V, Hamada H, Pardoll DM, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 90:3539
12. 12. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397
13. 13. Gansbacher B, Finstad CL, Gastl G, Guarini A, Bosl G, Gilboa G, Bander NH (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820
14. 14. Geiger J, Wagner P, Shu S, Chang AE (1992) A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1:199
15. 15. Gilboa E (1996) Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 23:101
16. 16. Golumbek PT, Lazenby AJ, Jaffee LM, Levitsky HI, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713
17. 17. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM (1993) Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53:5841-5844
18. 18. Greenberg P (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
19. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 160:3444-3452
20. 20. Hart I (1979) The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97:587
21. 21. Kurane S (1997) Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery. Ann Surg Oncol 4:579
22. 22. Leo O, Foo M, Sachs D, Samelson L, Bluestone J (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374
23. 23. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625
24. 24. Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang NS (1996) Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 7:1535
25. + T cells after gene gun immunization. J Exp Med 188:1075-1082
26. 26. Rakhmilevich A, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS (1996) Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291
27. 27. Rosenberg S, Spiess P, Lafreniere P (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318
28. 28. Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhai H (1995) Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother 17:201
29. 29. Tahara H, Lotze M, Robins P, Storkus W, Zitvogel L (1995) IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 6:1607
30. 30. Weber J, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med 166:1716
31. 31. Wexler H (1966) Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36:641
32. 32. Yang NS, Burkholder J, Roberts B, Sun WH, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB (1990) In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 87:9568
33. 33. Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729